Merck Seeks Additional Claims For Gardasil
This article was originally published in The Pink Sheet Daily
Executive Summary
sBLA includes data showing protection against two additional gynecological cancers.
You may also be interested in...
Gardasil Gains Blockbuster Status In Its First Year On The Market
Merck’s HPV vaccine generated $1.1 billion in sales year-to-date, firm reports during third quarter earnings call.
Gardasil Gains Blockbuster Status In Its First Year On The Market
Merck’s HPV vaccine generated $1.1 billion in sales year-to-date, firm reports during third quarter earnings call.
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.